Capricor Therapeutics Inc. Releases Investor Presentation Highlighting Progress in Duchenne Muscular Dystrophy Program and Exosome Platform Development
Reuters
Oct 13, 2025
<a href="https://laohu8.com/S/CAPR">Capricor Therapeutics Inc</a>. Releases Investor Presentation Highlighting Progress in Duchenne Muscular Dystrophy Program and Exosome Platform Development
Capricor Therapeutics Inc. has released a new investor presentation outlining key developments in its pipeline and financial position. The company highlighted progress in its Duchenne muscular dystrophy (DMD) program, including the anticipated topline data from the HOPE-3 Phase 3 clinical trial expected in the fourth quarter of 2025. Capricor also provided updates on its StealthX exosome platform, including ongoing Phase 1 studies in collaboration with NIAID. The presentation notes a cash balance of $123 million as of June 30, 2025, with a projected operational runway into the fourth quarter of 2026. Additionally, Capricor stands to receive up to $80 million in milestone payments upon potential U.S. approval of its DMD therapy, with additional sales-based milestones and the possibility of monetizing a Priority Review Voucher. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.